{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:35:01Z","timestamp":1774528501253,"version":"3.50.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jaut.2011.05.006","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T05:48:28Z","timestamp":1308462508000},"page":"136-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Complement and cytokine based therapeutic strategies in myasthenia gravis"],"prefix":"10.1016","volume":"37","author":[{"given":"Erdem","family":"T\u00fcz\u00fcn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruksana","family":"Huda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Premkumar","family":"Christadoss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2011.05.006_bib1","first-page":"159","article-title":"Myasthenia gravis","volume":"88","author":"Vincent","year":"2002","journal-title":"Adv Neurol"},{"key":"10.1016\/j.jaut.2011.05.006_bib2","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaut.2011.05.006_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib4","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2011.05.006_bib6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1749-6632.1987.tb51291.x","article-title":"Complement-mediated muscle damage produced by myasthenic sera","volume":"505","author":"Childs","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2011.05.006_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1981.tb33730.x","article-title":"The immunopathology of acquired myasthenia gravis","volume":"377","author":"Engel","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2011.05.006_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/jnnp.43.7.601","article-title":"Mechanisms of acetylcholine receptor loss in myasthenia gravis","volume":"43","author":"Drachman","year":"1980","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaut.2011.05.006_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1615\/CritRevImmunol.v25.i4.40","article-title":"Immune function of C1q and its modulators CD91 and CD93","volume":"25","author":"Tarr","year":"2005","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib10","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/intimm\/dxh159","article-title":"Antigen localization within the splenic marginal zone restores humoral immune response and IgG class switch in complement C4-deficient mice","volume":"16","author":"Zachrau","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3181\/00379727-105-26050","article-title":"Changes in serum complement activity in patients with myasthenia gravis","volume":"105","author":"Nastuk","year":"1960","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.jaut.2011.05.006_bib12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.jaut.2011.05.006_bib13","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaut.2011.05.006_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in\u00a0vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jaut.2011.05.006_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nmd.2005.11.005","article-title":"Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis","volume":"16","author":"T\u00fcz\u00fcn","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jaut.2011.05.006_bib17","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.4049\/jimmunol.172.9.5743","article-title":"Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS\/J mice","volume":"172","author":"T\u00fcz\u00fcn","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib18","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2019seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jaut.2011.05.006_bib19","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1167\/iovs.07-0271","article-title":"A\u00a0new mouse model of autoimmune ocular myasthenia gravis","volume":"48","author":"Yang","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaut.2011.05.006_bib20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaut.2011.05.006_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","article-title":"Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis","volume":"71","author":"Piddlesden","year":"1996","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib22","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","article-title":"Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6","volume":"142","author":"Biesecker","year":"1989","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib23","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaut.2011.05.006_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","article-title":"Pros and cons of treating murine myasthenia gravis with anti-C1q antibody","volume":"182","author":"T\u00fcz\u00fcn","year":"2007","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.transci.2004.07.014","article-title":"Immunoadsorption therapy and complement activation","volume":"32","author":"Pt\u00e1k","year":"2005","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.jaut.2011.05.006_bib27","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","article-title":"C5 gene influences the development of murine myasthenia gravis","volume":"140","author":"Christadoss","year":"1988","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4049\/jimmunol.1003252","article-title":"The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss","volume":"186","author":"Liang","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.03.007","article-title":"C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis","volume":"196","author":"Qi","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib31","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jneuroim.2006.01.015","article-title":"Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis","volume":"174","author":"T\u00fcz\u00fcn","year":"2006","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jneuroim.2008.12.013","article-title":"Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis","volume":"208","author":"Li","year":"2009","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib34","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.4049\/jimmunol.165.10.5867","article-title":"Attenuation of experimental autoimmune demyelination in complement-deficient mice","volume":"165","author":"Nataf","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jaut.2011.05.006_bib36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.expneurol.2006.06.003","article-title":"Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia","volume":"202","author":"Kaminski","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jaut.2011.05.006_bib37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jneuroim.2006.07.016","article-title":"Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis","volume":"181","author":"T\u00fcz\u00fcn","year":"2006","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib39","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/00207450601125840","article-title":"High interleukin-10 production is associated with anti-acetylcholine receptor antibody production and treatment response in juvenile myasthenia gravis","volume":"117","author":"Yapici","year":"2007","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.jaut.2011.05.006_bib40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2011.05.006_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/gene.2009.61","article-title":"A\u00a0functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis","volume":"11","author":"Heckmann","year":"2010","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaut.2011.05.006_bib42","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaut.2011.05.006_bib43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0165-5728(02)00030-9","article-title":"Role of IL-5 during primary and secondary immune response to acetylcholine receptor","volume":"125","author":"Poussin","year":"2002","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib44","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4049\/jimmunol.169.2.1077","article-title":"Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production","volume":"169","author":"Deng","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib45","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.4049\/jimmunol.157.12.5675","article-title":"IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis","volume":"157","author":"Deng","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/1521-4141(200101)31:1<225::AID-IMMU225>3.0.CO;2-0","article-title":"Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis","volume":"31","author":"Huang","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib47","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.4049\/jimmunol.175.3.2018","article-title":"IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1","volume":"175","author":"Yang","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib48","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.4049\/jimmunol.161.6.2856","article-title":"The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis","volume":"161","author":"Balasa","year":"1998","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4049\/jimmunol.170.1.604","article-title":"Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL\/6 mice","volume":"170","author":"Ostlie","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0165-5728(00)00385-4","article-title":"Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR","volume":"111","author":"Poussin","year":"2000","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib52","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.4049\/jimmunol.178.11.7072","article-title":"C57BL\/6 mice genetically deficient in IL-12\/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells","volume":"178","author":"Wang","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib53","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.4049\/jimmunol.164.10.5236","article-title":"Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL\/6 mice","volume":"164","author":"Karachunski","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib54","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1096\/fj.01-0072com","article-title":"Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18","volume":"15","author":"Im","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.jaut.2011.05.006_bib55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0165-5728(01)00473-8","article-title":"Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein","volume":"122","author":"Christadoss","year":"2002","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib56","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0165-5728(00)00420-3","article-title":"Lymphotoxin-alpha deficiency completely protects C57BL\/6 mice from developing clinical experimental autoimmune myasthenia gravis","volume":"113","author":"Goluszko","year":"2001","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0165-5728(01)00474-X","article-title":"Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis","volume":"122","author":"Goluszko","year":"2002","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib58","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/intimm\/12.10.1381","article-title":"Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis","volume":"12","author":"Wang","year":"2000","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib59","series-title":"Myasthenia gravis: disease mechanisms and immune intervention","first-page":"327","article-title":"Targeting classical complement pathway and IL-6","author":"Tuzun","year":"2010"},{"key":"10.1016\/j.jaut.2011.05.006_bib60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-5728(00)00259-9","article-title":"Interleukin-12 enhances clinical experimental autoimmune myasthenia gravis in susceptible but not resistant mice","volume":"107","author":"Sitaraman","year":"2000","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib61","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4049\/jimmunol.172.1.97","article-title":"The susceptibility to experimental myasthenia gravis of STAT6-\/- and STAT4-\/- BALB\/c mice suggests a pathogenic role of Th1 cells","volume":"172","author":"Wang","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib62","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.4049\/jimmunol.162.7.3775","article-title":"Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis","volume":"162","author":"Zhang","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib63","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1084\/jem.186.3.385","article-title":"Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice","volume":"186","author":"Balasa","year":"1997","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaut.2011.05.006_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jaut.2011.05.006_bib65","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00011-009-0087-6","article-title":"Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17\/Th1 to a Th2 and FoxP3+ regulatory T-cell profile","volume":"59","author":"Yang","year":"2010","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jaut.2011.05.006_bib66","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/eji.200838729","article-title":"BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO","volume":"39","author":"Kong","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib68","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1212\/01.WNL.0000147242.92691.71","article-title":"Etanercept treatment in corticosteroid-dependent myasthenia gravis","volume":"63","author":"Rowin","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jaut.2011.05.006_bib69","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-2249.2004.02585.x","article-title":"Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis","volume":"138","author":"Adikari","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib70","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nbd.2004.03.017","article-title":"Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells","volume":"16","author":"Duan","year":"2004","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jaut.2011.05.006_bib71","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1196\/annals.1405.023","article-title":"Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis","volume":"1132","author":"Meriggioli","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaut.2011.05.006_bib72","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cellimm.2006.08.005","article-title":"The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis","volume":"241","author":"Xiao","year":"2006","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib73","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/clim.1999.4822","article-title":"Myocytes respond to both interleukin-4 and interferon-gamma: cytokine responsiveness with the potential to influence the severity and course of experimental myasthenia gravis","volume":"94","author":"Stegall","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib74","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cyto.2006.05.009","article-title":"Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells","volume":"35","author":"T\u00fcz\u00fcn","year":"2006","journal-title":"Cytokine"},{"key":"10.1016\/j.jaut.2011.05.006_bib75","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","article-title":"Eculizumab for paroxysmal nocturnal haemoglobinuria","volume":"373","author":"Parker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2011.05.006_bib76","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.molimm.2003.10.017","article-title":"ScFv-mediated in\u00a0vivo targeting of DAF to erythrocytes inhibits lysis by complement","volume":"40","author":"Spitzer","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib77","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.4049\/jimmunol.156.11.4429","article-title":"IFN-gamma up-regulates expression of the complement components C3 and C4 by stabilization of mRNA","volume":"156","author":"Mitchell","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2011.05.006_bib78","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaut.2010.06.003","article-title":"Moutsopoulos: a lifetime in autoimunity","volume":"35","author":"Youinou","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaut.2010.06.005","article-title":"Update on the genetics and genomics of PBC","volume":"35","author":"Juran","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib80","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaut.2010.06.008","article-title":"The odd couple: a fresh look at autoimmunity and immunodeficiency","volume":"35","author":"Mackay","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaut.2010.06.012","article-title":"Activation of the type I interferon pathway in primary Sjogren\u2019s syndrome","volume":"35","author":"Mavragani","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib82","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jaut.2010.06.018","article-title":"Pathogenetic aspects of systemic lupus erythematosus with an emphasis on reglatory T cells","volume":"35","author":"Scheinecker","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib83","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaut.2010.06.019","article-title":"Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells","volume":"35","author":"Wiik","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib84","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.autrev.2010.05.014","article-title":"The international symposium on Sjogren\u2019s syndrome in Brest: the \"top of the tops\" at the \"tip of the tips\"","volume":"9","author":"Youinou","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2011.05.006_bib85","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.autrev.2010.05.007","article-title":"The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjogren\u2019s syndrome","volume":"9","author":"Saraux","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2011.05.006_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2010.09.006","article-title":"Systemic lupus erythematosus and the SLE galaxy","volume":"10","author":"Meroni","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2011.05.006_bib87","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: an update","volume":"10","author":"Katz","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2011.05.006_bib88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.autrev.2010.08.004","article-title":"Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges","volume":"10","author":"Andreoli","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2011.05.006_bib89","doi-asserted-by":"crossref","first-page":"J163","DOI":"10.1016\/j.jaut.2009.12.005","article-title":"Geo-epidemiology and autoimmunity","volume":"34","author":"Youinou","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib90","doi-asserted-by":"crossref","first-page":"J178","DOI":"10.1016\/j.jaut.2009.11.013","article-title":"Nucleic acid-association autoantigens: pathogenic involvement and therapeutic potential","volume":"34","author":"Hoffmann","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib91","doi-asserted-by":"crossref","first-page":"J226","DOI":"10.1016\/j.jaut.2009.11.006","article-title":"Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract","volume":"34","author":"Powell","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib92","doi-asserted-by":"crossref","first-page":"J247","DOI":"10.1016\/j.jaut.2009.11.011","article-title":"Light, including ultraviolet","volume":"34","author":"Maverakis","year":"2010","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib93","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.autrev.2010.02.006","article-title":"Wegener\u2019s granulomatosis vasculitis and granuloma","volume":"9","author":"Schilder","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2011.05.006_bib94","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.autrev.2010.02.013","article-title":"Current remedies for vitiligo","volume":"9","author":"Tahir","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2011.05.006_bib95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaut.2009.07.007","article-title":"Navigating the passage between Charybdis and Scylla: recognizing the achievements of Noel Rose","volume":"33","author":"Ansari","year":"2009","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib96","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jaut.2009.09.006","article-title":"Clustering and commonalities among autoimmune diseases","volume":"33","author":"Mackay","year":"2009","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib97","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaut.2009.09.009","article-title":"Sjogren syndrome: advances in the pathogenesis from animal models","volume":"33","author":"Chiorini","year":"2009","journal-title":"J\u00a0Autoimun"},{"key":"10.1016\/j.jaut.2011.05.006_bib98","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaut.2009.09.004","article-title":"Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function","volume":"33","author":"Kong","year":"2009","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jaut.2011.05.006_bib99","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jaut.2009.07.009","article-title":"Autoimmune myocarditis: past, present and future","volume":"33","author":"Leuschner","year":"2009","journal-title":"J\u00a0Autoimmun"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841111000485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841111000485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:03:50Z","timestamp":1760256230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841111000485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0896841111000485"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2011.05.006","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement and cytokine based therapeutic strategies in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2011.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}